Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Kyverna Therapeutics, Inc. (KYTX)

5.67 -0.18 (-3.08%)
At close: 4:00:01 PM EDT
5.67 +0.01 (+0.27%)
After hours: 4:00:03 PM EDT
Trade KYTX on Coinbase
Chart Range Bar
Loading chart for KYTX
  • Previous Close 5.85
  • Open 5.74
  • Bid 4.22 x 200
  • Ask 7.18 x 200
  • Day's Range 5.55 - 5.87
  • 52 Week Range 5.16 - 13.67
  • Volume 640,116
  • Avg. Volume 828,337
  • Market Cap (intraday) 350.652M
  • Beta (5Y Monthly) 2.06
  • PE Ratio (TTM) --
  • EPS (TTM) -2.93
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 30.40
  • Zacks Rating Bearish

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

kyvernatx.com

149

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KYTX
39.68%
S&P 500 (^GSPC)
10.73%

1-Year Return

KYTX
16.00%
S&P 500 (^GSPC)
11.11%

3-Year Return

KYTX
81.19%
S&P 500 (^GSPC)
81.91%

5-Year Return

KYTX
81.19%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -38.32M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

25.00
30.40 Average
5.67 Current
33.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/3/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 25 -> 25

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    361.47M

  • Enterprise Value

    195.05M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.17

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -44.51%

  • Return on Equity (ttm)

    -87.24%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -152.64M

  • Diluted EPS (ttm)

    -2.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    199.43M

  • Total Debt/Equity (mrq)

    19.93%

  • Levered Free Cash Flow (ttm)

    -107.68M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.67 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: